Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation

References

• Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–994.
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Fabbrocini G, Cacciapuoti S, et al. Ocular Manifestations in psoriasis screening (OcMaps) questionnaire: a useful tool to reveal misdiagnosed ocular involvement in Psoriasis. J Clin Med. 2021;10(5):1031. DOI:10.3390/jcm10051031
   PubMed Web of Science ®Google Scholar
• Furue K, Ito T, Tsuji G, et al. Psoriasis and the TNF/IL23/IL17 axis. G Ital Dermatol Venereol. 2019;154(4):418–424. DOI:10.23736/S0392-0488.18.06202-8
   PubMed Web of Science ®Google Scholar
• Peter C van de Kerkhof. From empirical to pathogenesis-based treatments for Psoriasis. J Invest Dermatol. 2022;142(7):1778–1785.
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Ruggiero A, et al. Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study. J DermatolTreat. 2022;33(5):2560–2564. DOI:10.1080/09546634.2022.2036674
   Google Scholar
• Megna M, Potestio L, Ruggiero A, et al. Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study. Dermatol Ther. 2022;35(7):e15524. DOI:10.1111/dth.15524
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Camela E, Potestio L, et al. Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge. Expert Opin Drug Saf. 2022;21(12):1445–1451. DOI:10.1080/14740338.2022.2160447
   PubMed Web of Science ®Google Scholar
• Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J DermatolTreat. 2022;33(6):2813–2820. DOI:10.1080/09546634.2022.2081655
   Google Scholar
• Ruggiero A, Fabbrocini G, Cinelli E, et al. Real world practice indirect comparison between guselkumab and risankizumab: results from an Italian retrospective study. Dermatol Ther. 2022;35(1):e15214. DOI:10.1111/dth.15214
   PubMed Web of Science ®Google Scholar
• Mansouri B, Patel M, Menter A. Biological therapies for psoriasis. Expert Opin Biol Ther. 2013;13(12):1715–1730.
   PubMed Web of Science ®Google Scholar
• Megna M, Ruggiero A, Battista T, et al. LoNg-term efficacy and safety of Risankizumab for moderate to severe Psoriasis: a 2-year real-life retrospective study. J Clin Med. 2023;12(9):3233. DOI:10.3390/jcm12093233
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Balato A, Enerbäck C, et al. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021;397(10275):754–766. DOI:10.1016/S0140-6736(21)00184-7
   PubMed Web of Science ®Google Scholar
• Hawkes JE, Yan BY, Chan TC, et al. Discovery of the IL-23/IL-17 signaling pathway and the treatment of Psoriasis. J Immunol. 2018;201(6):1605–1613. DOI:10.4049/jimmunol.1800013
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Camela E, et al. Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: results from an Italian single-center retrospective study in a real-life setting. Dermatol Ther. 2022;35(9):e15667. DOI:10.1111/dth.15667
   PubMed Web of Science ®Google Scholar
• Freitas E, Blauvelt A, Torres T. Bimekizumab for the treatment of Psoriasis. Drugs. 2021;81(15):1751–1762.
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert Opin Drug Saf. 2023 Jan;22(1):25–41.
   PubMed Web of Science ®Google Scholar
• Griffith SK, Ahn GS, Wu JJ. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 2021;385(12):1149–1150.
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo-controlled phase 3 trial. Lancet. 2021;397(10273):487–498. DOI:10.1016/S0140-6736(21)00125-2
   PubMed Web of Science ®Google Scholar
• Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385(2):142–152. DOI:10.1056/NEJMoa2102383
   PubMed Web of Science ®Google Scholar
• Clinical trial from clinicaldatabase.gov. A study to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (BE BRIGHT). Available from: https://www.clinicaltrials.gov/ct2/show/NCT03598790?term=BE+BRIGHT&draw=2&rank=1. Accessed Mar 13, 2023.
   Google Scholar
• Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;397(10273):475–486. [published correction appears in Lancet. 2021 Mar 27;397(10280):1182]. DOI:10.1016/S0140-6736(21)00126-4
   PubMed Web of Science ®Google Scholar
• Bimekizumab (BIMZELX). Summary of product characteristic - drug insert package. Available from: https://www.ema.europa.eu/en/documents/product-information/bimzelx-epar-product-information_en.pdf (last access Mar 8, 2023).
   Google Scholar
• Adams R, Maroof A, Baker T, et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 2020;11:1894.
   PubMed Web of Science ®Google Scholar
• Glatt S, Helmer E, Haier B, et al. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. 2017;83(5):991–1001. DOI:10.1111/bcp.13185
   PubMed Web of Science ®Google Scholar
• Oliver R, Krueger JG, Glatt S, et al. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study. Br J Dermatol. 2022;186(4):652–663. DOI:10.1111/bjd.20827
   PubMed Web of Science ®Google Scholar
• Oliveira DG, Faria R, Torres T. An overview of bimekizumab for the treatment of psoriatic arthritis: the evidence so far. Drug Des Devel Ther. 2021;15:1045–1053.
   PubMed Web of Science ®Google Scholar
• Papp KA, Merola JF, Gottlieb AB, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018;79(2):277–286.e10. DOI:10.1016/j.jaad.2018.03.037
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Merola JF, et al. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study. J Am Acad Dermatol. 2020;83(5):1367–1374. DOI:10.1016/j.jaad.2020.05.105
   PubMed Web of Science ®Google Scholar
• Strober B, Paul C, Blauvelt A,et al. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial. J Am Acad Dermatol. 2023;S0190–9622(23)00782-X.
   Google Scholar
• Asahina A, Okubo Y, Morita A, et al. Bimekizumab efficacy and safety in Japanese patients with Plaque Psoriasis in BE VIVID: a Phase 3, Ustekinumab and Placebo-controlled study. Dermatol Ther (Heidelb). 2023;13(3):751–768. DOI:10.1007/s13555-022-00883-y
   PubMed Web of Science ®Google Scholar
• Thaçi D, Vender R, de Rie MA, et al. Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial. Br J Dermatol. 2023;188(1):22–31. DOI:10.1093/bjd/ljac021
   PubMed Web of Science ®Google Scholar
• Potestio L, Genco L, Villani A, et al. Reply to ‘Cutaneous adverse effects of the available COVID-19 vaccines in India: a questionnaire-based study’ by Bawane Jet al. J Eur Acad Dermatol Venereol. 2022;36(11):e863–864. DOI:10.1111/jdv.18341
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Megna M, Fabbrocini G, et al. Video and telephone teledermatology consultations during COVID-19 in comparison: patient satisfaction, doubts and concerns. Clin Exp Dermatol. 2022;47(10):1863–1864. DOI:10.1111/ced.15286
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Picone V, Martora F, et al. Guselkumab, Risankizumab, and Tildrakizumab in the management of Psoriasis: a review of the real-world evidence. Clin Cosmet Investig Dermatol. 2022;15:1649–1658.
   PubMed Web of Science ®Google Scholar
• Gkalpakiotis S, Cetkovska P, Arenberger P, et al. RisankizuMab for the treatment of moderate-to-severe Psoriasis: real-life multicenter experience from the Czech republic. Dermatol Ther (Heidelb). 2021;11(4):1345–1355. DOI:10.1007/s13555-021-00556-2
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert Opin Drug Saf. 2023 Jan;22(1):43–58.
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Fabbrocicni G, Cacciapuoti S, et al. Tildrakizumab for the treatment of moderate-to-severe Psoriasis: results froM 52 weeks real-life retrospective study. Clin Cosmet Investig Dermatol. 2023;16:529–536.
   PubMed Web of Science ®Google Scholar
• Valenti M, Gargiulo L, Ibba L, et al. Sub-erythrodermic psoriasis successfully treated with bimekizumab: a case report. Dermatol Ther. 2022;35(12):e15952. DOI:10.1111/dth.15952
   PubMed Web of Science ®Google Scholar
• Megna M, Battista T, Potestio L, et al. A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab. J Cosmet Dermatol. 2023;22(3):1146–1148. DOI:10.1111/jocd.15543
   PubMed Web of Science ®Google Scholar
• Shukuin R, Koizumi H, Ebata A, et al. Successful combination therapy of bimekizumab and granulocyte monocyte adsorption apheresis for generalized pustular psoriasis complicated with microscopic polyangiitis. J Dermatol. 2023. DOI:10.1111/1346–8138.16707
   PubMed Web of Science ®Google Scholar
• Oliveira Mde F, Rocha Bde O, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015 Jan;90(1):9–20.
   PubMed Web of Science ®Google Scholar
• Agarwal K, Das A, Das S, et al. Impact of Psoriasis on quality of life. Indian J Dermatol. 2022;67(4):387–391.
   PubMed Web of Science ®Google Scholar
• Rendon A, Schäkel K. Psoriasis Pathogenesis and treatment. Int J Mol Sci. 2019 Mar 23;20(6):1475.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Maffei M, Patruno C, et al. Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis. Dermatol Ther. 2021;34(6):e15120. DOI:10.1111/dth.15120
   PubMed Web of Science ®Google Scholar
• Camela E, Potestio L, Fabbrocini G, et al. New frontiers in personalized medicine in psoriasis. Expert Opin Biol Ther. 2022;22(12):1431–1433.
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Fabbrocini G, et al. Tildrakizumab: a new therapeutic option for erythrodermic psoriasis? Dermatol Ther. 2021;34(5):e15030.
   PubMed Web of Science ®Google Scholar
• Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77(4):523–532.
   PubMed Web of Science ®Google Scholar
• Adams R, Maroof A, Baker T, et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 2020;21(11):1894.
   Google Scholar
• Ruggiero A, Potestio L, Camela E, et al. Bimekizumab for the treatment of Psoriasis: a review of the current knowledge. Psoriasis (Auckl). 2022;12:127–137.
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Megna M, Fabbrocini G, et al. Drug safety evaluation of ixekizumab for psoriasis: a review of the current knowledge. Expert Opin Drug Saf. 2022;21(10):1249–1257.
   PubMed Web of Science ®Google Scholar
• Marasca C, Fornaro L, Martora F, et al. Onset of vitiligo in a psoriasis patient on ixekizumab. Dermatol Ther. 2021;34(5):e15102.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG, Warren RB, et al. Bimekizumab safety in patients with moderate to severe plaque Psoriasis: poOled results from phase 2 and phase 3 randomized clinical trials. JAMA Dermatol. 2022;158(7):735–744.
   PubMed Web of Science ®Google Scholar
• Armstrong A, Paul C, Puig L, et al. Safety of ixekizumab treatment for up to 5 years in adult patients with moderate-to-severe psoriasis: results from greater than 17,000 patient-years of exposure. Dermatol Ther (Heidelb). 2020;10(1):133–150.
   PubMed Web of Science ®Google Scholar
• Papp KA, Bachelez H, Blauvelt A, et al. Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2017;177(6):1537–1551.
   PubMed Web of Science ®Google Scholar
• Megna M, Ocampo-Garza SS, Potestio L, et al. New-onset PsorIatic arthritis under biologics in Psoriasis patients: an increasing challenge? Biomedicines. 2021;9(10):1482.
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Fabbrocini G, Cinelli E, et al. Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison. J Am Acad Dermatol. 2021;85(4):1028–1030.
   PubMed Web of Science ®Google Scholar
• Lockshin B, Cronin A, Harrison RW, et al. Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: the Corrona Psoriasis registry. Dermatol Ther. 2021;34(2):e14808.
   PubMed Web of Science ®Google Scholar
• Marasca C, Ruggiero A, Fontanella G, et al. Telemedicine and support groups could be used to improve adherence to treatment and health-related quality of life in patients affected by inflammatory skin conditions during the COVID-19 pandemic. Clin Exp Dermatol. 2020;45(6):749.
   PubMed Web of Science ®Google Scholar
• Marasca C, Ruggiero A, Napolitano M, et al. May COVID-19 outbreaks lead to a worsening of skin chronic inflammatory conditions? Med Hypotheses. 2020;143:109853.
   PubMed Web of Science ®Google Scholar
• Costanzo A, Russo F, Galluzzo M, et al. Secukinumab exhibits sustained and stable response in patients with moderate-to-severe Psoriasis: results from the SUPREME study. Acta Derm Venereol. 2021;101(10):adv00576.
   PubMedGoogle Scholar
• Zagaria O, Villani A, Ruggiero A, et al. New-onset lichen planus arising after COVID-19 vaccination. Dermatol Ther. 2022;35(5):e15374.
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Cacciapuoti S, et al. Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real-life study. Dermatol Ther. 2022;35(12):e15941.
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Ibba L, Pavia G, et al. Real-life effectiveness and safety of Risankizumab in 131 patients affected by moderate-to-severe plaque Psoriasis: a 52-week retrospective study. Dermatol Ther (Heidelb). 2022;12(10):2309–2324.
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Martora F. Picone V the impact of COVID-19 infection on patients with psoriasis treated with biologics: an Italian experience. Clin Exp Dermatol. 2022 Dec;47(12):2280–2282.
   PubMed Web of Science ®Google Scholar
• Marasca C, Annunziata MC, Camela E, et al. Teledermatology and inflammatory skin conditions during COVID-19 era: new perspectives and applications. J Clin Med. 2022 10;11(6):1511.
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Fabbrocini G, et al. Treating psoriasis in the elderly: biologics and small molecules. Expert Opin Biol Ther. 2022;22(12):1503–1520.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Mallbris L, Warren RB, et al. Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study. Br J Dermatol. 2016;175(3):487–492.
   PubMedGoogle Scholar
• Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21(1):111.
   PubMed Web of Science ®Google Scholar
• Peter CM van de Kerkhof, Griffiths CEM, Reich K, et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(1):83–98.e4.
   PubMed Web of Science ®Google Scholar
• De Lucia M, Potestio L, Costanzo L, et al. Scabies outbreak during COVID-19: an Italian experience. Int J Dermatol. 2021;60(10):1307–1308.
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Battista T, et al. Immune response to COVID-19 mRNA vaccination in patients with psoriasis undergoing treatment with biologics. Clin Exp Dermatol. 2022;47(12):2310–2312.
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Villani A, et al. Teledermatology: a useful tool also after COVID-19 era? J Cosmet Dermatol. 2022;21(6):2309–2310.
   PubMed Web of Science ®Google Scholar
• Valenti M, Costanzo A. Efficacy and safety of switching psoriatic patients to bimekizumab: new evidence from clinical trials. Br J Dermatol. 2023;188(3):316–317.
   PubMed Web of Science ®Google Scholar
• Farahnik B, Beroukhim K, Nakamura M, et al. Anti-IL-17 agents for Psoriasis: a review of phase III data. J Drugs Dermatol. 2016;15(3):311–316.
   PubMedGoogle Scholar